In the life sciences sector, acquisitions, mergers, investments and international expansion processes require much more in-depth evaluations than in other industries.
In the pharmaceutical, biotech, medical devices and healthcare world, in fact, the value of a company does not depend solely on economic or commercial data, but also on the strength of its regulatory system and the level of regulatory compliance achieved.
It is precisely in this context that regulatory due diligence takes on a strategic role.
For investors, CEOs, and entrepreneurs, properly analyzing regulatory aspects means reducing risks, avoiding unexpected costs, and understanding the true value of the company being acquired or partnered.
What is regulatory due diligence
Regulatory due diligence is an in-depth verification activity aimed at assessing the regulatory compliance of a company operating in the life sciences sector.
The goal is not only to identify any nonconformities, but to understand:
- the maturity level of the quality system
- The sustainability of existing permits
- the reliability of technical documentation
- The regulatory risk associated with corporate activity
- The company’s ability to maintain compliance over time
In the pharmaceutical and medical sector, even seemingly minor critical issues can generate major consequences for business value, operations, and the ability to market products in certain markets.
Why it is crucial in M&A transactions
During merger & acquisition (M&A) transactions, regulatory due diligence allows us to verify whether the target company is truly operating in compliance with applicable regulations.
A business may appear economically sound but hide regulatory issues that can undermine the entire operation.
The main aspects analyzed include:
- authorizations and operating licenses
- Compliance with applicable regulations (GMP/ GDP, MDR/IVDR) and adopted quality standards (e.g., ISO 13485)
- status of inspections received
- detour management and CAPA
- technical documentation and regulatory files
- management of qualified suppliers
- Pharmacovigilance activities or post-market surveillance
- Third-party contracts and regulatory responsibilities
- management of regulatory changes
Incomplete evaluation of these elements may result in:
- delays in the operation
- high remediation costs
- trading blocks
- regulatory sanctions
- loss of authorizations
- reduction in estimated enterprise value
The Swiss and international context
In the Swiss context, life sciences companies operate within a particularly strict and dynamic regulatory framework.
Activities may be subject to oversight by agencies such as Swissmedic, as well as European and international regulations, especially in cases of export or presence in multiple markets.
This makes regulatory due diligence even more important in the operations of:
- acquisition of pharmaceutical companies
- international expansion
- opening of new operational offices
- strategic partnerships
- investments by funds or venture capital
- integration of complex supply chains
For investors, understanding the level of regulatory exposure is as critical as assessing revenue, EBITDA, or business prospects.
The most critical areas to check
Effective regulatory due diligence must be structured and multidisciplinary.
Some of the most sensitive areas include:
Quality Management System
The presence of up-to-date procedures, documented controls and traceable processes is a key indicator of business maturity.
A fragile quality system increases the risk of future noncompliance.
GMP/GDP Compliance
In the pharmaceutical sector, any critical issues related to Good Manufacturing Practice or Good Distribution Practice can have immediate impacts on business continuity.
Regulatory documentation
Incomplete dossiers, outdated documents or technical inconsistencies may jeopardize authorizations and registrations.
Previous audits and inspections
Analysis of internal audits, regulatory inspections, and any observations received allows the company’s true compliance status to be assessed.
Supplier management
Life sciences companies depend heavily on external partners and qualified suppliers.
Insufficient supply chain management can pose a significant risk.
Also a strategic element for startups and scale-ups
Regulatory due diligence is not only about large multinational corporations or complex operations.
Even biotech startups, innovative companies, and growth-stage entities can benefit enormously from a prior review of their regulatory structure.
Many investors today consider compliance an essential parameter in risk assessment.
A company with sound regulatory processes conveys greater reliability, reduces uncertainties and increases its attractiveness in the market.
Preparing in advance also allows you to:
- accelerate investment processes
- improve corporate credibility
- Reduce future corrective costs
- Avoid delays in international growth
Due diligence as a value tool
Due diligence is often perceived exclusively as an audit activity.
In fact, if managed correctly, it represents a strategic tool for value creation.
In fact, a thorough regulatory assessment makes it possible to:
- identify areas for improvement
- strengthen the quality system
- increase corporate transparency
- improve internal governance
- Facilitate future extraordinary transactions
In the life sciences sector, where compliance and business continuity are closely linked, the regulatory component cannot be treated as a secondary issue.
Conclusions
In the pharmaceutical and life sciences world, regulatory compliance is as much a strategic asset as economic performance.
During M&A transactions, investments, or expansion processes, thorough regulatory due diligence enables the identification of hidden risks, protection of investment value, and greater long-term sustainability.
For CEOs, investors and entrepreneurs, integrating regulatory assessment into decision-making processes means taking a more informed, structured and growth-oriented approach.